Biofrontera INC

Biofrontera Inc. announced robust second quarter 2026 financial results, highlighted by a 32.9% increase in net product revenue to $12.0 million and a significant improvement in gross margin to 80%.

Biofrontera Inc. held its Annual Meeting of Stockholders on June 11, 2026, where key director elections, an incentive plan amendment, and auditor ratification were approved.

Biofrontera Inc. announced first quarter 2026 financial results, showcasing a 17% revenue increase to $10.1 million and significant gross margin expansion to 80%, alongside progress in its clinical pipeline.

Biofrontera Inc. announced record fourth quarter and full year 2025 financial results, driven by strong Ameluz sales and a favorable new earnout structure.

Biofrontera announced a favorable U.S. Patent Office decision, finding all challenged claims of Sun Pharma's 11,697,028 patent unpatentable, though other litigation continues.

Biofrontera Inc. announced positive and statistically significant top-line results from its Phase 3 clinical trial for Ameluz PDT in treating actinic keratoses on the extremities, neck, and trunk.

Biofrontera Inc. reported a 32.9% increase in product revenue for Q2 2026, driven by higher Ameluz sales, but continues to face substantial doubt regarding its going concern status and significant operational challenges from regulatory actions.

Biofrontera Inc. announced its first quarter 2026 financial results, reporting a 17.4% increase in net product revenue to $10.1 million, driven by higher Ameluz sales.

Biofrontera Inc. reported a narrowed nine-month net loss, completed a strategic acquisition of Ameluz rights, and sold its Xepi product line, while addressing Nasdaq compliance issues.

Biofrontera Inc. reported increased product revenue but a widened Q2 net loss, alongside critical Nasdaq compliance issues and a going concern warning, while securing US rights to its core products and raising $8.5M in new capital.

Biofrontera Inc. saw a revenue increase in Q1 2025 but faces substantial doubt about its ability to continue as a going concern due to liquidity issues and Nasdaq compliance concerns.

Biofrontera Inc. announced its third quarter 2024 results, highlighting a slight revenue increase but also acknowledging substantial doubt about its ability to continue as a going concern.

Biofrontera Inc. files an amendment to its 2025 annual report on Form 10-K/A, primarily to include an exhibit and new certifications.

Biofrontera Inc. reported an 11.8% revenue increase and reduced net loss in 2025, driven by a strategic acquisition and cost efficiencies, despite facing substantial doubt about its ability to continue as a going concern.

Biofrontera Inc. reports a revenue increase in 2024 driven by Ameluz sales and the launch of RhodoLED XL, but acknowledges substantial doubt about its ability to continue as a going concern.

Biofrontera Inc.'s 10-K filing details the terms of its common stock, warrants, and stockholder rights plan, including voting rights, dividend entitlements, and anti-takeover provisions.

Hermann Luebbert, CEO & Chairman and a Director of Biofrontera Inc., reported multiple transactions in common stock on July 28, 2026.

Eugene Frederick Leffler, Chief Financial Officer of Biofrontera Inc., reported multiple transactions in common stock on July 28, 2026.

Biofrontera Inc. Director Kevin Daniel Weber reported the acquisition of 20,000 employee stock options with an exercise price of $0.90.

Biofrontera Inc. CEO and Chairman Hermann Luebbert acquired common stock and received new equity awards, including restricted stock units and stock options.

Biofrontera Inc.'s Chief Financial Officer, Eugene Frederick Leffler, received new grants of restricted stock units and stock options, alongside the conversion of previously awarded restricted stock units into common shares.

Biofrontera Inc. Director Heikki Lanckriet was granted 20,000 employee stock options with an exercise price of $0.9, vesting monthly over one year.

Biofrontera Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026, to vote on director elections, an increase in equity plan shares, and auditor ratification.

Biofrontera Inc. is seeking stockholder approval for a reverse stock split to maintain Nasdaq listing and to enable full conversion and voting rights for recently issued Series C and Series D Preferred Stock.

Biofrontera Inc. has filed a supplement to its 2025 Annual Meeting proxy statement, clarifying that two key proposals, including an increase in authorized shares, are now considered routine matters by the NYSE, allowing brokers to vote uninstructed shares.

Biofrontera Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on key proposals including a share increase and director election.

Biofrontera Inc. is asking stockholders to approve an amendment to its 2021 Omnibus Incentive Plan to increase the number of shares available for issuance at the upcoming annual meeting on June 12, 2024.

Biofrontera Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on the election of directors and ratification of the company's auditor.

Biofrontera Inc. files an S-1 registration statement for the resale of 4,000,640 common shares by selling stockholders, with no proceeds going to the company.

Biofrontera Inc. announces the acquisition of full U.S. rights to its key product Ameluz and a significant common stock resale offering by selling stockholders, while facing ongoing financial challenges and potential dilution.

Biofrontera Inc. has filed an S-1 registration statement to allow selling stockholders to resell 13,602,176 shares of common stock issued from the conversion of Series C Convertible Preferred Stock, with the company not receiving any proceeds from these sales.

Biofrontera Inc. has filed a registration statement for the resale of up to 5.7 million shares of common stock by selling stockholders, primarily stemming from the conversion of senior secured convertible notes.

Biofrontera Inc. has filed a registration statement for the potential resale of up to 11,309,019 shares of common stock by selling stockholders, issuable upon conversion of Series B-3 Convertible Preferred Stock.

Biofrontera Inc. has filed an amendment to its registration statement for the resale of up to 9,310,678 shares of common stock by selling stockholders.

Biofrontera AG has converted Series D Preferred Stock into common shares of Biofrontera Inc., increasing its beneficial ownership to 19.54% and securing board representation rights.

Biofrontera AG and related entities updated their beneficial ownership in Biofrontera Inc. following a new agreement for U.S. rights to Ameluz and RhodoLED, involving a royalty structure and the issuance of convertible preferred stock.

Rosalind Advisors, Inc. and affiliated entities have filed a Schedule 13G, reporting a beneficial ownership of 9.9% in Biofrontera Inc., with significant details on potential share issuances.

Rosalind Advisors and affiliated entities report a 9.9% passive beneficial ownership in Biofrontera Inc., primarily through common stock, preferred shares, and convertible debt, subject to a 9.99% ownership blocker.

AIGH Capital Management LLC and Orin Hirschman report a 7.9% beneficial ownership stake in Biofrontera Inc. as of December 31, 2025.

Rosalind Advisors, Steven Salamon, Gilad Aharon, and Rosalind Master Fund L.P. jointly report a 9.9% beneficial ownership in Biofrontera Inc. common shares.

Rosalind Advisors and related entities report a 9.9% beneficial ownership in Biofrontera Inc., constrained by a 9.99% blocker provision on convertible securities.

Laurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 3.5% of Biofrontera Inc.'s common stock as of March 31, 2025.